KR20160019769A - Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising cordycepin or a pharmaceutically acceptable salt thereof - Google Patents

Abstract

Provided in the present invention are: a composition comprising a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient for whitening the skin, improving the elasticity of the skin, reducing wrinkles, moisturizing the skin, or having anti-inflammatory activities; particularly a cosmetic composition; a pharmaceutical composition; and a health food product. The cosmetic or pharmaceutical composition of the present invention is safe to the human body with reduced side effects, and has excellent effects in whitening the skin, improving the elasticity of the skin, reducing wrinkles, moisturizing the skin, having anti-inflammatory activities, etc.

Description

TECHNICAL FIELD [0001] The present invention relates to a cosmetic or pharmaceutical composition for skin whitening, elasticity, wrinkle-improving, moisturizing or anti-inflammation, which comprises cocondene or a pharmaceutically acceptable salt thereof, inflammatory < / RTI > comprising cordycepin or a pharmaceutically acceptable salt thereof.

The present invention relates to a cosmetic composition, a pharmaceutical composition and a health food having excellent effects such as skin whitening, elasticity, wrinkle improvement, moisturizing or anti-inflammation, The present invention also relates to a cosmetic composition, a pharmaceutical composition and a health food which can exert such effects even in a small amount.

It is a common desire to have white skin. The color or brightness of the skin is genetically determined by the concentration and distribution of melanin in the human skin, but is also influenced by environmental or physiological conditions such as sun UV, fatigue or stress. Melanin is produced by a nonenzymatic oxidation reaction of tyrosine, which is a kind of amino acid, by the enzyme tyrosinase, which is converted to DOPA and Dopaquinone. The pathway for the formation of melanin is known, but the mechanism by which the melanin synthesis induces tyrosinase is not yet elucidated.

On the other hand, commonly known whitening ingredients include substances inhibiting the activity of tyrosinase enzymes such as kojic acid or arbutin, hydroquinone, vitamin C (L-ascorbic acid) There are plant extracts. By inhibiting the synthesis of melanin pigment, they can brighten the skin tone to realize skin whitening, and it is possible to improve skin hypercholesterolemia such as stain or freckles due to ultraviolet rays, hormones or heredity. However, when applied to skin, there is a problem that the use amount is limited due to safety problems such as irritation and redness, or the effect is insignificant, so that a practical effect can not be expected.

Collagen is a major substrate protein produced in the fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical durability of the skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, cell division and differentiation (Induction of growth of an organism or wound healing) are known. Such collagen is reduced by photoaging by age and ultraviolet irradiation, and collagenase activity, which degrades collagen, promotes collagen reduction. This is known to be closely related to the formation of wrinkles in the skin.

In addition, Elastin fiber forms crosslinks with collagen and is a skin constituent important for wrinkle formation involved in skin elasticity. The deficiency and aggregation of elastin fibers and the marked increase in the activity of the elastin degrading enzyme Elastase have been found to be one of the causes of skin wrinkles. It is known that Elastase is the only enzyme capable of degrading elastin, and its inhibition can fundamentally reduce the wrinkles of the skin.

On the other hand, collagen and elastin fibers are substrate proteins that play an important role in water retention in the dermal layer. These protein proteins adsorb moisture and increase the water holding capacity inside the structure, thereby allowing the skin to maintain proper moisture content. And it is known to be involved in maintaining the elasticity of the skin.

Presently, retinoids, adenosine, animal placenta-derived proteins, chlorella extract, and the like are known to improve wrinkles. The best known retinol promotes collagen synthesis and inhibits elastase enzymes, but it is unstable. When applied to the skin, it has a limited use due to safety problems such as irritation and redness, and chlorella extract has little effect, It is known that it is difficult to expect a wrinkle-improving effect.

Glycation generally refers to a reaction in which a simple sugar such as glucose or fructose forms a covalent bond to a protein or fat that occurs without involvement of the enzyme. The glycation takes place through a series of chemical reactions known as amarylidation, maillard reaction, resulting in the formation of advanced glycation endproducts (AGEs).

On the other hand, the glycation process of the protein does not involve the enzymatic action, so it occurs slowly, and as a result, the protein having a longer half-life such as collagen has more influence. Analysis of the final glycation products revealed that the more aged the glycated collagen was accumulated, the accumulation of the final glycated product changed the protein to a harder and more brittle state, and the glycated collagen was found in the extracellular matrix of the dermal layer (Dyer, DG et al., The Journal of Clinical Investigation., 9, p. 2463, 1993), which inhibits skin elasticity and promotes wrinkle formation by preventing collagen from forming a proper structure

Also, it is known that the final saccharification product produced by saccharification is a brownish substance and accumulates on the dermal layer as the skin ages. It is believed that as the aging of the skin progresses gradually, the face light turns yellow and it is known that the reflection light reflected from the skin decreases as the specific final saccharification product accumulates. While the amount of melanin pigment in the skin is not related to skin aging, the final glycation product accumulated in the dermal layer of the skin gradually increases in amount as the skin ages, and the skin color becomes dull (Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009)

Aminoguanidine, pyridoxamine, and aspirin are known to inhibit glycation. However, these substances are limited in their use due to the safety of the skin, There is a problem that can not be expected.

Inflammation is the immune response of the body in response to a wound or disease. Oxidative stresses such as ultraviolet rays, active oxygen, and free radicals activate inflammatory factors and cause aging of various diseases and skin. Kinin, Plasmin or Complement, which are vasoactive polypeptides, have vasodilatation, contraction and chemotaxis action, as well as lymphokines such as interleukin-6 (IL-6) Phosphorus and arachidonic acid are responsible for inflammation. Arachidonic acid is metabolized through the two pathways of cyclooxygenase or lipoxygenase and is metabolized to inflammation mediator Prostaglandin or Lukotriene to mediate various inflammatory responses.

On the other hand, in order to eliminate inflammation, elimination of inflammation source, reduction of vital reaction and symptoms is called anti-inflammatory. Flutenamic acid, ibuprofen, benzydamine or indomethacin are non-steroidal drugs used for anti-inflammatory purposes. Prednisolone, a steroid, Or dexamethasone. It is also known that allantoin, azene or hydrocortisone are effective for anti-inflammation. However, these substances have a problem that they can not be expected to effectively reduce the inflammation because of their limited use due to the safety of the skin, have.

Accordingly, it is possible to provide skin whitening, elasticity, wrinkle improvement, moisturizing and anti-inflammatory effects that are superior to living body-safe, effective ingredients, and more effective than those having existing skin whitening, elasticity, wrinkle, moisturizing and anti- It is urgently required to develop a component having an amino acid sequence.

Accordingly, the present invention is to solve these problems and to provide such a useful use of a new active ingredient, i.e., an active ingredient, which is safe to human body and has good skin whitening, elasticity, wrinkle improvement, moisturizing or anti-

In other words, a problem to be solved by the present invention is to provide a composition comprising the active ingredient having excellent efficacy as an active ingredient.

In order to solve the above-mentioned problems, the present invention provides a method for treating skin whitening, improving elasticity, improving wrinkles, moisturizing or anti-inflammatory (improving skin troubles) comprising cordycepin or a pharmaceutically acceptable salt thereof as an active ingredient, , Preferably a cosmetic composition, a pharmaceutical composition or a health food.

That is, the present invention provides a novel use of codisepine or a pharmaceutically acceptable salt thereof for skin whitening, elasticity enhancement, wrinkle improvement, moisturizing or anti-inflammation.

The inventors of the present invention confirmed that codisepin inhibits collagenase and elastase activity of skin and promotes regeneration of skin by exhibiting antagonism effect and has moisturizing effect, skin elasticity and wrinkle reducing effect Thereby completing the invention. Further, it has been confirmed that the above-mentioned cordycepin suppresses NO production and has an anti-inflammatory effect and suppresses melanin synthesis, thereby exhibiting a whitening effect, and thus completed the present invention.

In the present invention, the 'whitening effect' refers to not only brightening the skin tone by inhibiting the synthesis of the melanin pigment but also improving skin hypercholesterolemia due to ultraviolet rays, hormones or heredity, such as spots or freckles.

In the present invention, the term 'improving elasticity or skin elasticity' means reducing the degree to which the skin is stuck or stretched. In addition, the elasticity means that elasticity of the skin is maintained in a state where elastin and collagen are sufficiently present.

In the present invention, the term " wrinkle-reducing effect " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already-generated wrinkles.

In the present invention, the term 'moisturizing or skin moisturizing' means increasing the skin moisture and maintaining a moist state. Skin moisturizing effect can help to improve wrinkles and elasticity of skin.

In the present invention, the term 'anti-inflammatory or inflammatory improvement' refers to inhibition of inflammation. The inflammation is one of biological tissue defense responses to a certain stimulus, and includes three types of tissue degeneration, circulatory disorder and exudate, and tissue proliferation It is a complicated lesion that accompanies. More specifically, inflammation is part of congenital immunity and, like in other animals, human congenital immunity recognizes a pattern of cell surfaces that are specifically present in a pathogen. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory reaction occurs. Inflammation is a nonspecific defense that creates hostile environments for microorganisms entering the wound. In the inflammatory response, white blood cells that are responsible for the early stage of immune response, when wounded or infected, enter the body to express cytokines. Therefore, the expression level of intracellular cytokine is an index of inflammatory response activation. Examples of skin diseases associated with inflammation include atopic dermatitis, psoriasis, radiation, chemical substances, inflammatory diseases caused by burns, acid burns, vesicular dermatosis, visceral type diseases, itching due to allergies, seborrheic eczema, rose acne, Inflammatory hair loss such as pemphigus vulgaris, polymorphous exudative erythema, erythema nodosum, erythematosus, pharyngitis, alopecia areata, skin T-cell lymphoma, and the like. In particular, the anti-inflammatory effect of the present invention can have an effect of improving skin troubles such as acne for example.

In order to solve the above-mentioned problems and to achieve the object of the present invention, the present invention provides a composition comprising a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.

[Chemical Formula 1]

The compound represented by Formula 1 has a molecular formula of C ₁₀ H ₁₃ N ₅ O ₃ and a molecular weight of 251.12. Cordycepin, 3'-deoxyadenosine, 3'-deoxy-adenosine 9-cordyceposidoadenine, -bD-erythro-pentofuranosyl) -9H-purin-6-amine, 9- (3-Deoxy-bD-ribofuranosyl) adenine.

The present invention is not particularly limited to the method for obtaining the above-mentioned cordycepsin, and may be chemically synthesized by a method known in the art, or a commercially available substance may be used.

In the cosmetic composition, the pharmaceutical composition and the health food according to the present invention, the content of the codispefin is preferably 0.00001 to 10% by weight based on the total weight of the cosmetic composition, the pharmaceutical composition and the health food.

"Pharmaceutically acceptable salts" of the present invention refer to salts prepared with or without toxic organic or inorganic acids, or bases.

The organic acid may be selected from the group consisting of formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, , Glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid-based salts, , Bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.

The above-mentioned acid addition salts may be obtained by a) directly mixing the compound of formula 1 and an acid, or b) dissolving and mixing one of them in a solvent or a water solvent, or c) Lt; RTI ID = 0.0 > acid < / RTI > in a solvent and mixing them.

In addition to the above, additionally saltable forms include, but are not limited to, the salts of gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, Aspartate and the like.

Pharmaceutically acceptable base addition salts include, but are not limited to, salts formed with sodium, potassium, calcium, ammonium, magnesium or organic amino.

The cordycepin of the present invention may be present in unsolvated form as well as solvated form including form of hydrate, ethanol, and the like. The cordycepsin of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.

The cosmetic composition for skin whitening, elasticity enhancement, wrinkle improvement, skin moisturizing and anti-inflammation according to the present invention can be used as a cosmetic composition for a skin, a cosmetic, a cosmetic, a cosmetics, The compositions of the present invention may be formulated as liquid cleansers, bath salts, sunscreen creams, sun oils, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant- containing cleansing oils, powder foundations, emulsion foundations, waxes, But are not limited thereto. ≪ Desc / Clms Page number 12 >

In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier incorporated in a cosmetic composition for general skin, and examples thereof include oil, water, a surfactant, a moisturizer, a lower alcohol, A thickening agent, a chelating agent, a coloring matter, an antiseptic, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.

The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulations. When the formulation of the present invention is an ointment, a paste, a cream or a gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide Mixtures of these may be used.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as the carrier component, Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, -Butyl glycol oil, and in particular fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiesters, fatty acid protein hydrolizates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars and the like are used as carrier components .

The present invention also provides skin whitening, elasticity enhancement, wrinkle improvement, skin moisturizing and anti-inflammatory methods, comprising applying the compound represented by Formula 1 to the skin of an individual. The subject includes, without limitation, mammals including rats, livestock, humans, and the like.

According to another embodiment of the present invention, there is provided a pharmaceutical composition for skin whitening, elasticity enhancement, wrinkle improvement, skin moisturizing or anti-inflammation containing the compound of formula (1) as an active ingredient.

The composition comprising the compound of the present invention may be various oral or parenteral formulations, but may preferably be a parenteral agent. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, and emulsions. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.

The present invention can also provide a skin external preparation for skin whitening, elasticity enhancement, wrinkle improvement, skin moisturizing and anti-inflammatory effect, which comprises the compound of formula (1) as an active ingredient.

When the compound of Formula 1 is used as an external preparation for skin, it may further contain at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickening and gelling agents, softening agents, antioxidants, suspending agents, stabilizers, foaming agents, A preservative, a vitamin, a blocking agent, a wetting agent, a essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, a lipid vesicle or a skin external preparation for oral administration in the form of an active agent, water, ionic or nonionic emulsifier, filler, sequestering agent and chelating agent And may contain adjuvants conventionally used in the field of dermatology, such as any other ingredient commonly used. The components can also be introduced in amounts commonly used in the field of dermatology.

When the compound of Formula 1 is provided as an external preparation for skin, it may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.

The pharmaceutical composition of the present invention is particularly preferably used as a parenteral preparation. For example, the external preparation for skin may be a pharmaceutically acceptable base such as vaseline or stearyl alcohol; Suitable pharmaceutically acceptable surfactants such as polysorbate, sorbitan sesquioleate, and the like; A suitable pharmaceutically acceptable humectant such as glycerin; A suitable pharmaceutically acceptable solvent; And a conventional external preparation for skin preparation in which a flavoring agent, a coloring agent, a stabilizer, a tackifier and the like are homogeneously mixed.

When the compound of Chemical Formula 1 of the present invention is used as a medicine, it may further contain one or more active ingredients showing the same or similar functions. For example, it may contain known skin whitening, elasticity enhancement, wrinkle improvement, moisturizing effect and anti-inflammatory component. The skin whitening, the elasticity enhancement, the wrinkle improvement, the moisturizing effect and the anti-inflammatory effect of the composition of the present invention can be further enhanced by including additional skin whitening, elasticity enhancement, wrinkle improvement, moisturizing effect and anti- When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. In one embodiment of the invention, the composition is a skin elasticity or wrinkle improving ingredient known in the art as retinoic acid, TGF, animal placenta-derived proteins, betulinic acid and chlorella extract; As a whitening ingredient known in the art, substances inhibiting tyrosinase enzyme activity such as kojic acid, arbutin, etc., hydroquinone, L-ascorbic acid; Anti-inflammatory components known in the art include, but are not limited to, COX-2 inhibitors, prednisolone and allantoin; And derivatives thereof, and various plant extracts. ≪ Desc / Clms Page number 2 > The additional component may be included in an amount of 0.0001 to 10% by weight based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety, ease of formulation of the compound of Formula 1 .

The pharmaceutical composition of the present invention can provide a desired skin whitening effect, elasticity improving effect, wrinkle improving effect, moisturizing effect and anti-inflammatory effect when an effective amount of the compound of Formula 1 is included. In the present invention, the term "effective amount" means the amount of a compound which exhibits a skin whitening effect, exhibits an improving effect of elasticity and wrinkle, or exhibits a moisturizing effect.

An effective amount of the compound of formula (1) contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, how the compound is applied to the skin, and the time on the skin. For example, when the composition is commercialized as a pharmaceutical product, the compound of Formula 1 may be contained at a higher concentration than that of a cosmetic product that is routinely applied to skin. Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of the compound of formula (1) 6 times a day.

According to another embodiment of the present invention, there is provided a health food for skin whitening effect, elasticity improving effect, wrinkle improving effect, moisturizing effect and anti-inflammatory effect comprising the compound of formula (1).

The term 'health food' as used herein means a food prepared by adding the compound of formula (1) to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering or suspension, But it has the advantage that there are no side effects that can occur when a drug is used for a long period of time using a food as a raw material. Since the health food of the present invention thus obtained can be ingested on a daily basis, a high skin whitening effect, an elasticity improving effect, a wrinkle reducing effect, and a moisturizing effect can be expected.

When the compound of Chemical Formula 1 is used as a food additive, the compound of Chemical Formula 1 may be added as it is or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range . There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense. The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention. In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the health food of the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

In one embodiment of the present invention, the composition may contain 0.00001 wt% to 10 wt% of the compound of Formula 1 based on the weight of the entire composition.

The composition containing the cordycepin of the present invention or a pharmaceutically acceptable salt thereof exhibits a skin whitening effect.

The composition containing the cordycepin of the present invention or a pharmaceutically acceptable salt thereof exhibits an effect of improving skin elasticity or improving wrinkles.

The composition containing the cordycepin of the present invention or a pharmaceutically acceptable salt thereof exhibits a skin moisturizing effect.

The composition containing the cordycepin of the present invention or a pharmaceutically acceptable salt thereof exhibits an anti-inflammatory effect or a skin trouble-improving effect.

The composition containing cordycepin of the present invention or a pharmaceutically acceptable salt thereof can be used as safe and excellent cosmetic ingredients and pharmaceutical ingredients.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. The embodiments of the present invention are provided by way of example to facilitate a specific understanding of the present invention.

Reference Example  1: Cordisceptin ( Cordycepin ) Material information

[Chemical Formula 1]

Material name: Codisepin

CAS No .: 73-03-0

Molecular formula: C ₁₀ H ₁₃ N ₅ O ₃

Molecular weight: 251.12

Where to buy: Nature standard, Tauto Biotech (China)

Example  1: Anti-inflammatory effect - NO  Generation inhibitory effect

In order to confirm the anti-inflammatory effect and the skin trouble relieving effect of the compound of formula (1), nitrite oxide (NO) formation inhibition test was carried out by the GRIESS method using RAW264.7 cell line (ATCC number: CRL-2278).

Specifically, RAW264.7 cells, macrophages of mice, were subcultured several times, placed in 24-well plates at 3 × 10 ⁵ per well, and cultured for 24 hours. Subsequently, the compound of formula (I) was replaced with a diluted cell culture medium at a concentration of 1, 10 and 100 ppm. At this time, L-NMMA (L-NG-Monomethylarginine), which is an inhibitor of NO production, was treated together as a positive control and cultured for 30 minutes. LPS (Lipopolysaccharide) . 100 μl of the supernatant was transferred to a 96-well plate, and 100 μl of the GRIESS solution was added thereto at room temperature for 10 minutes. The absorbance at 540 nm was measured to determine the NO inhibitory effect of the compound of formula (1) The results are shown in Table 1 below.

NO production inhibitory effect (number of repeats = 3) of the substance of formula (1)

sample NO production inhibition rate (%) Control group (DMSO, 10 ppm) - L-NMMA (positive control, 10 ppm) 41.02 The compound of formula (1) (1 ppm) 10.34 The compound of formula (1) (10 ppm) 14.71 The compound of formula (1) (100 ppm) 22.96

As can be seen from the results of Table 1, it was confirmed that the compound of Chemical Formula (1) exhibits excellent activity as a natural substance when compared with L-NMMA which is a representative anti-inflammatory drug, although its activity is low.

It can be used singly in a pharmaceutical or cosmetic composition for improving anti-inflammation or skin troubles, but also has anti-inflammatory effect as an auxiliary effect in whitening, wrinkle improvement or skin trouble improvement, so that a synergistic effect can be expected

Example  2: Collagenase  Activity inhibitory effect

The inhibitory effect of collagenase, an enzyme that degrades collagen, was confirmed as follows.

Collagenase used collagenase derived from rat's interest and N- (3- [2-Furyl] acryloyl) -Leu-Gly-Pro-Ala was used as a collagenase substrate. The buffer solution used was a solution of 50 mM Tricine, 10 mM CaCl ₂ .H ₂ O, 400 mM NaCl (pH 7.5) dissolved therein. The synthetic substrate was dissolved in a buffer solution at a concentration of 10 mM and finally diluted to 75 μM. The collagenase was dissolved at a concentration of 1 unit / ml using cold third distilled water at 4 ° C and then diluted with buffer solution to a final concentration of 0.05 unit / ml. Collagenase inhibition candidates were tested at final concentrations of 25 and 50 ppm. At this time, the positive control group was set to have a final concentration of 50 ppm of epigallocatechin gallate (EGCG) whose collagenase inhibitory effect was known. The reaction was carried out in a 96-well plate and allowed to react at room temperature for 10 minutes. Absorbance was measured at 345 nm using a spectrophotometer at intervals of 1 minute, and the maximum slope of absorbance versus time was determined to determine the activity of the enzyme. Collagenase inhibition rates were calculated as follows.

Inhibition of Collagenase Activity of Compound (1) (Number of Repeats = 3)

sample Enzyme activity Inhibition rate (%) The compound of formula (1) (50 ppm) -0.3 57.14 The compound of formula (1) (25 ppm) -0.4 42.88 The positive control (EGCG, 50 ppm) -0.6 14.28 The control (DMSO, 50 ppm) -0.7 -

As can be seen from the results shown in Table 2, the compound of Chemical Formula 1 is more excellent in inhibiting collagenase activity than EGCG, which is a positive control. That is, the compound of formula (1) exerts excellent collagenase activity inhibitory effect. Therefore, it was found that the compound of Chemical Formula 1 can be used for skin regeneration and wrinkle improvement.

Example  3: Elastase  Active inhibitory effect

The activity inhibitory effect of Elastase, an enzyme that degrades elastin, was confirmed as follows.

Elastase used Elastase from human leukocyte cells and MeOSuc-Ala-Ala-Pro-Val-pNA as synthetic substrate for Elastase. The buffer solution used was 100 mM Tris (pH 7.5) solution. Finally, 0.2 mU was used for the ELASTASES using a buffer solution. In addition, the synthetic substrate of Elastase was diluted with buffer solution to make a final concentration of 0.5 mM by making a 100 mM solution using DMSO. At this time, the positive control group was set to contain 10 ppm of quercetin, which is known as an ELASTIC inhibitor. Ella stase inhibition candidates were added to give a final concentration of 10, 20 ppm. The reaction was carried out in a 96-well plate and allowed to react at room temperature for 20 minutes. Absorbance was measured at 405 nm using a spectrophotometer at intervals of 1 minute, and the slope of absorbance versus time was determined as the activity of the enzyme. Ella stasis inhibition rates were calculated as follows.

Inhibitory effect of the compound of formula (1) on elastase activity (number of repeats = 3)

sample Enzyme activity Inhibition rate (%) The compound of formula (1) (20 ppm) 5.1 50.96 The compound of formula (1) (10 ppm) 7.9 24.04 The positive control (Quercetin, 10 ppm) 3.5 66.35 The control (DMSO, 20 ppm) 10.4 -

As can be seen from the results shown in Table 3, when the compound of Chemical Formula 1 was treated, the effect was less than that of the positive control, but the inhibition of the elastase activity was excellent. That is, the compound of formula (1) exerted a superior inhibitory effect on elastase activity. Therefore, it was found that the compound of Chemical Formula 1 can be used for skin regeneration and wrinkle improvement.

Example  4: whitening effect - melanin total amount reduction effect

The compound of Chemical Formula 1 was added to the culture solution of mouse melanoma cells (B-16 mouse) to determine the whitening effect by measuring the total amount of melanin at the cellular level (Lotan R., Lotan D. Cancer Res . 40: 3345-3350, 1980). To evaluate the toxicity of melanoma cells in rats before the experiment, whitening evaluation was performed by selecting a concentration that is not toxic.

The compound of the formula (1) was added to the culture medium to give final concentrations of 1 ppm and 10 ppm, and the control group, arbutin, was added to the medium so as to be treated with B-16 melanoma cells and cultured for 3 days.

Cells were then trypsinized, detached from the culture, centrifuged, and then melanin was extracted. The removed cells were incubated with 1 ml of sodium hydroxide solution (1N concentration), boiled for 10 minutes to dissolve melanin, and the absorbance was measured at 400 nm using a spectrophotometer to measure the amount of melanin produced.

The amount of melanin was measured by the absorbance at 1 × 10 ⁶ cells per unit cell, and the total amount of melanin relative to the control group was calculated as the inhibition rate (%). The results are summarized in Table 4.

Reduction of total melanin levels at the cellular level by concentration

sample Melanin production
(abs) Inhibition rate (%) Control group (DMSO, 10 ppm) 0.33 - Positive control (arbutin, 100 ppm) 0.228 31.06 The compound of formula (1) (10 ppm) 0.207 37.41 The compound of formula (1) (1 ppm) 0.262 20.63

As can be seen from the results of the above Table 4, the compound of the formula (1) has a better inhibitory effect on melanin formation even when a smaller concentration is applied to cultured rat melanoma cells as compared with arbutin known as a whitening substance , Indicating less total melanin content.

Therefore, it was found that the compound of formula (1) can be used for whitening purposes.

Example  5: Antialcification  effect

In order to confirm the anti-glycation effect, the saccharification inhibitory activity was measured using L-arginine and glucose.

First, dissolve 1 M L-arginine and 1 M glucose in 1 M phosphate buffer (pH 7.4) and dilute the sample to 50 and 100 ppm using 1M phosphate buffer solution. Mix 1 M L-arginine and 1 M phosphate buffer at a ratio of 1: 4, and dispense 80 μl each into 96-well plates. Add 100 μl of 0.01 M aminoguanidine to be used as a positive control and a sample diluted to 50 and 100 ppm, respectively. Mix these samples well and then add glucose diluted in 1 M phosphate buffer to a final concentration of 0.1 M glucose. And reacted at 70 ° C for 4 hours. The degree of saccharification was measured by measuring the absorbance of the 96-well plate at 420 nm using a spectrophotometer.

Glycation in the following formula is an experimental group in which 1M L-arginine and 1M glucose were added to induce glycation. To measure the absorbance of the sample itself, add 1M L-arginine and sample without glucose and measure the absorbance at 420 nm Respectively. The saccharide inhibitory activity can be obtained by the following formula.

The antagonism effect of the compound of formula (1)

sample Inhibition rate (%) The control (DMSO, 50 ppm) - The positive control (Aminoguanidine, 55 ppm) 54.89 The compound of formula (1) (50 ppm) 51.08 The compound of formula (1) (25 ppm) 27.93

As can be seen from the results of Table 5, the compound of formula (I) shows excellent antagonism effect and is thought to have a whitening or wrinkle-reducing effect.

Claims (6)

A composition for skin whitening comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]

A composition for improving skin elasticity or wrinkle comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]

1. A composition for anti-inflammation comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]

1. A skin moisturizing composition comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]

The composition according to any one of claims 1 to 4, wherein the composition is used as a cosmetic composition, a pharmaceutical composition or a health food. The composition according to any one of claims 1 to 4, wherein the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof is contained in an amount of 0.00001 to 10% by weight based on the total weight of the composition.